{"id":139571,"date":"2026-08-03T08:28:30","date_gmt":"2026-08-03T08:28:30","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/139571\/"},"modified":"2026-08-03T08:28:30","modified_gmt":"2026-08-03T08:28:30","slug":"obesity-battle-heats-up-again-as-novo-claws-its-way-back-into-race-with-lilly","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/139571\/","title":{"rendered":"Obesity battle heats up again as Novo claws its way back into race with Lilly"},"content":{"rendered":"<p>London \u2013 Novo Nordisk investors have found little cause for optimism during a bruising two-year period of profit warnings, leadership upheaval and a sliding share price as rival Eli Lilly streaked ahead. Now, they may have reason for hope.<\/p>\n<p>Despite Novo having lost ground in injectable GLP-1s in recent years, the Danish obesity drugmaker is getting a boost from its new Wegovy weight-loss pill that \u200bis holding onto its lead against Lilly\u2019s more recently launched Foundayo.<\/p>\n<p>The pair are battling for dominance in the obesity drug market, which analysts expect \u200cto be \u200cworth more than $100 billion by the end of the decade in the United States alone. Novo\u2019s shares have climbed some \u200b35% from a March low, with the company looking to go on the offensive \u2014 including with a divisive court case against Lilly over what it calls misleading marketing in the vital U.S. market.<\/p>\n","protected":false},"excerpt":{"rendered":"London \u2013 Novo Nordisk investors have found little cause for optimism during a bruising two-year period of profit&hellip;\n","protected":false},"author":2,"featured_media":139572,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[276,67098,272,357,358],"class_list":["post-139571","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-eli-lilly","tag-glps","tag-novo-nordisk","tag-obesity","tag-pharmaceuticals"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117030637085737422","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/139571","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=139571"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/139571\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/139572"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=139571"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=139571"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=139571"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}